Rhabdomyolysis is a syndrome resulting from acute skeletal muscle necrosis, with subsequent massive release of muscle cell components into the circulation. Although the pathophysiology as well as the clinical aspects of rhabdomyolysis have been quite well investigated, the physician should be alert in case a patient presents with the syndrome, as it may be complicated with acute kidney injury which increases mortality. In addition, the causes of rhabdomyolysis are multiple, with drugs being responsible most of the times. In the field of oncology, the complexity of patients’ symptoms and the continuous introduction of new medicines make the diagnosis of any clinical entity challenging. The oncologist should always include rhabdomyolysis in the differential diagnosis of related symptoms (the classic triad of myalgias, muscle weakness and urine hyperpigmentation). Early treatment decreases the duration of rhabdomyolysis and may prevent acute kidney injury. Bevacizumab is an anti-VEGF agent indicated in the treatment of numerous neoplastic diseases. Rhabdomyolysis is not usual after chemotherapy or monoclonal antibody administration. We observed and here present a case of rhabdomyolysis after bevacizumab therapy in a patient with nonsmall cell lung cancer and we subsequently review the aspects of rhabdomyolysis. Our aim is to alert physicians treating oncology patients in rhabdomyolysis, as a rare adverse effect of anticancer drugs.